In this episode of Future Fuzz, Vince Quinn dives into counter positioning with Shawn Malloy, VP of Marketing at Lindus Health, a company challenging the norms of clinical trials. Shawn unpacks what it means to be an "anti-CRO" in a highly regulated, legacy-dominated industry. He shares how Lindus is transforming clinical research by integrating technology, aligning incentives, and cutting out outdated inefficiencies. This conversation is a must-listen for marketers interested in challenger brand strategy, healthcare disruption, or just building something radically better.
Guest Bio
Shawn Malloy is the VP of Marketing at Lindus Health, a company redefining how clinical trials are run by taking on legacy CROs with speed, transparency, and integrated tech. With a background in engineering and late-stage drug development, Shawn brings deep industry experience from his time at large pharmaceutical companies. His unique perspective, having worked both in product development and now on the marketing frontlines, fuels his passion for creating meaningful, customer-centric change in the healthcare space.
Takeaways
Chapters
00:00 – Intro: What is an Anti-CRO?
01:32 – Why CROs are Broken
03:45 – Stagnation in Clinical Trial Methods
05:30 – Counter Positioning: Shaking Up the Industry
07:19 – Educating the Market on New Models
08:25 – Broken Incentives and Overruns
09:40 – Vertical Integration: Lindus’s Full Tech Stack
11:00 – Shawn’s Shift from Engineering to Marketing
13:45 – Empathy Through Firsthand Experience
16:30 – Building a Challenger Brand: Where to Start
18:38 – Connect with Shawn
Follow Shawn Malloy on LinkedIn here
Follow Vince Quinn on LinkedIn here